Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection

doi:10.3748/wjg.v32.i3.114176

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 3

This Article

(50)

(42)

(0)

(1)

(693)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Jan 21, 2026; 32(3): 114176
Published online Jan 21, 2026. doi: 10.3748/wjg.v32.i3.114176

Table 1 Baseline characteristics, n (%)

Variables	Before IPTW				After IPTW
Variables	HCV mono-infection (n = 792)	HIV/HCV co-infection (n = 112)	P value	SMD	HCV mono-infection (n = 792)	HIV/HCV co-infection (n = 112)	P value	SMD
Age, years	58.0 (51.0-67.0)	44.0 (36.0-53.5)	< 0.001	0.96	46.0 (37.0-54.0)	44.0 (36.0-53.0)	0.829	0.04
Sex			< 0.001	1.16			0.465	0.09
Male	339 (42.8)	101 (90.2)			691 (87.3)	101 (90.2)
Female	453 (57.2)	11 (9.8)			101 (12.7)	11 (9.8)
Diabetes mellitus			0.35	0.11			0.891	0.02
Absent	685 (86.5)	101 (90.2)			710 (89.7)	101 (90.2)
Present	107 (13.5)	11 (9.8)			82 (10.3)	11 (9.8)
Hypertension			0.187	0.15			0.975	0.004
Absent	657 (86.5)	99 (88.4)			699 (88.3)	99 (88.4)
Present	107 (13.5)	13 (11.6)			93 (11.7)	13 (11.6)
Genotype			< 0.001	0.4			0.428	0.2
1	507 (64.0)	52 (46.4)			430 (54.3)	52 (46.4)
2	233 (29.4)	42 (37.5)			281 (35.5)	42 (37.5)
Others	52 (6.6)	18 (16.1)			81 (10.2)	18 (16.1)
Treatment			< 0.001	0.47			0.808	0.11
None	51 (6.4)	26 (23.2)			151 (19.9)	26 (23.2)
Peginterferon plus ribavirin	212 (26.8)	30 (26.8)			247 (31.2)	30 (26.8)
DAA	529 (66.8)	56 (50.0)			386 (48.8)	56 (50.0)
Liver cirrhosis			< 0.001	0.23			0.109	0.31
Absent	639 (80.7)	96 (85.7)			706 (89.2)	96 (85.7)
Present	153 (19.3)	11 (9.8)			86 (10.8)	11 (9.8)
Unknown	0 (0.0)	5 (4.5)			0 (0.0)	5 (4.5)
Child-Pugh score			0.282	0.16			0.295	0.23
A5	663 (87.8)	34 (81.0)			689 (87.0)	91 (81.1)
A6	65 (9.0)	8 (19.0)			89 (11.2)	15 (13.3)
B7	15 (2.1)	4 (4.3)			10 (1.2)	5 (4.4)
B8	6 (0.8)	1 (1.1)			4 (0.5)	1 (1.1)
B9	2 (0.3)	0 (0.0)			2 (0.2)	0 (0.0)
AFP (ng/mL)	4.6 (2.9-8.4)	2.9 (2.1-5.4)	< 0.001	0.14	4.3 (2.5-6.8)	2.8 (2.0-5.3)	0.253	0.09
ALBI score	-2.8 (-3.0 to -2.5)	-2.8 (-3.1 to -2.5)	0.306	0.05	-2.9 (-3.0 to -2.6)	-2.8 (-3.1 to -2.5)	0.78	0.04
APRI	0.7 (0.4-1.4)	0.7 (0.3-1.3)	0.346	0.04	0.5 (0.3-1.0)	0.7 (0.3-1.3)	0.085	0.23
Fibrosis-4 index	2.4 (1.5-4.2)	1.6 (1.0-2.7)	< 0.001	0.18	1.3 (0.8-2.4)	1.6 (1.0-2.7)	0.23	0.16

IPTW: Inverse probability of treatment weighting; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; DAA: Direct-acting antiviral; AFP: Alpha-fetoprotein; ALBI: Albumin-bilirubin score; APRI: Aspartate aminotransferase to platelet ratio index.

Full Size Table

Citation: Park J, Jeong JY, Kim SS, Yoon JH, Eun HS, Choi J, Yoon KT, Jung YK, Park SY, Gwak GY, Kim DY, Kim JH, Lee JW, Kim TY, Jang JW, Yu SJ. Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection. World J Gastroenterol 2026; 32(3): 114176
URL: https://www.wjgnet.com/1007-9327/full/v32/i3/114176.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i3.114176

Park J, Jeong JY, Kim SS, Yoon JH, Eun HS, Choi J, Yoon KT, Jung YK, Park SY, Gwak GY, Kim DY, Kim JH, Lee JW, Kim TY, Jang JW, Yu SJ. Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection. World J Gastroenterol 2026; 32(3): 114176 [PMID: 41640617 DOI: 10.3748/wjg.v32.i3.114176]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.